BiotechTube

Inebilizumab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin G4-related Disease

Conditions

Immunoglobulin G4-related Disease

Trial Timeline

Apr 3, 2026 → Jun 10, 2031

NCT ID
NCT07222553

About Inebilizumab

Inebilizumab is a phase 2 stage product being developed by Amgen for Immunoglobulin G4-related Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07222553. Target conditions include Immunoglobulin G4-related Disease.

What happened to similar drugs?

0 of 4 similar drugs in Immunoglobulin G4-related Disease were approved

Approved (0) Terminated (0) Active (4)
🔄iptacopanNovartisPhase 3
🔄Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
🔄Felzartamab + PlaceboBiogenPhase 3
🔄sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT06987539Phase 2Recruiting
NCT07222553Phase 2Recruiting
NCT06180278ApprovedActive
NCT05549258Phase 2Recruiting
NCT04540497Phase 3Active

Competing Products

11 competing products in Immunoglobulin G4-related Disease

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
39
zigakibartNovartisPhase 2
42
iptacopanNovartisPhase 3
47
CCX168AmgenPhase 2
35
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
47
rilzabrutinib + GlucocorticoidsSanofiPhase 2
35
FelzartamabBiogenPhase 2
32
Felzartamab + PlaceboBiogenPhase 3
44
SparsentanTravere TherapeuticsPhase 2
29
SparsentanTravere TherapeuticsPhase 2
33
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
38